Compile Data Set for Download or QSAR
Report error Found 36 Enz. Inhib. hit(s) with all data for entry = 12452
Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM703875(US20240368151, Compound Int17)
Affinity DataKi:  0.410nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor and the LSD binding site of the 5-HT2B receptor w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2B(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM21342((4R,7R)-N,N-diethyl-6-methyl-6,11-diazatetracyclo[...)
Affinity DataKi:  0.420nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM703873(US20240368151, Compound Int14)
Affinity DataKi:  0.470nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor and the LSD binding site of the 5-HT2B receptor w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM703868(US20240368151, Compound 11)
Affinity DataKi:  0.690nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor and the LSD binding site of the 5-HT2B receptor w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM703861(US20240368151, Compound 7)
Affinity DataKi:  0.850nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor and the LSD binding site of the 5-HT2B receptor w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM21342((4R,7R)-N,N-diethyl-6-methyl-6,11-diazatetracyclo[...)
Affinity DataKi:  0.890nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor and the LSD binding site of the 5-HT2B receptor w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM703881(US20240368151, Compound 20)
Affinity DataKi:  1.03nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor and the LSD binding site of the 5-HT2B receptor w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM703855(US20240368151, Compound 1)
Affinity DataKi:  1.06nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor and the LSD binding site of the 5-HT2B receptor w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM50008224(CHEMBL66335 | 7-Methyl-4,6,6a,7,8,9-hexahydro-indo...)
Affinity DataKi:  1.07nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor and the LSD binding site of the 5-HT2B receptor w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM703860(US20240368151, Compound 6)
Affinity DataKi:  1.16nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor and the LSD binding site of the 5-HT2B receptor w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM703859(US20240368151, Compound 3)
Affinity DataKi:  1.36nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor and the LSD binding site of the 5-HT2B receptor w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM703882(US20240368151, Compound 21)
Affinity DataKi:  1.93nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor and the LSD binding site of the 5-HT2B receptor w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM703864(US20240368151, Compound 5)
Affinity DataKi:  2.18nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor and the LSD binding site of the 5-HT2B receptor w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM703878(US20240368151, Compound 16)
Affinity DataKi:  2.18nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor and the LSD binding site of the 5-HT2B receptor w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM703869(US20240368151, Compound Int11)
Affinity DataKi:  2.22nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor and the LSD binding site of the 5-HT2B receptor w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM703877(US20240368151, Compound 13)
Affinity DataKi:  2.23nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor and the LSD binding site of the 5-HT2B receptor w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM703866(US20240368151, Compound 8)
Affinity DataKi:  2.38nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor and the LSD binding site of the 5-HT2B receptor w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM703857(US20240368151, Compound 2)
Affinity DataKi:  2.79nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor and the LSD binding site of the 5-HT2B receptor w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM703862(US20240368151, Compound 4)
Affinity DataKi:  3.07nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor and the LSD binding site of the 5-HT2B receptor w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2B(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM703860(US20240368151, Compound 6)
Affinity DataKi:  3.33nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM703879(US20240368151, Compound 18)
Affinity DataKi:  3.41nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor and the LSD binding site of the 5-HT2B receptor w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2B(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM703859(US20240368151, Compound 3)
Affinity DataKi:  4.09nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2B(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM703857(US20240368151, Compound 2)
Affinity DataKi:  4.10nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM703880(US20240368151, Compound 19)
Affinity DataKi:  5.58nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor and the LSD binding site of the 5-HT2B receptor w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM703876(US20240368151, Compound 12)
Affinity DataKi:  5.61nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor and the LSD binding site of the 5-HT2B receptor w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2B(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM703862(US20240368151, Compound 4)
Affinity DataKi:  17.7nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM703884(US20240368151, Compound 23)
Affinity DataKi:  26.6nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor and the LSD binding site of the 5-HT2B receptor w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM703858(US20240368151, Compound 3a)
Affinity DataKi:  27.6nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor and the LSD binding site of the 5-HT2B receptor w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM703883(US20240368151, Compound 22)
Affinity DataKi:  28.4nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor and the LSD binding site of the 5-HT2B receptor w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM703867(US20240368151, Compound 10)
Affinity DataKi:  32.7nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor and the LSD binding site of the 5-HT2B receptor w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM703874(US20240368151, Compound Int17a)
Affinity DataKi:  41.3nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor and the LSD binding site of the 5-HT2B receptor w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM703872(US20240368151, Compound Int14a)
Affinity DataKi:  56.2nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor and the LSD binding site of the 5-HT2B receptor w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM703863(US20240368151, Compound 5a)
Affinity DataKi:  74.5nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor and the LSD binding site of the 5-HT2B receptor w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM703870(US20240368151, Compound Int8a)
Affinity DataKi:  84.3nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor and the LSD binding site of the 5-HT2B receptor w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM703856(US20240368151, Compound 2a)
Affinity DataKi:  115nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor and the LSD binding site of the 5-HT2B receptor w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM703865(US20240368151, Compound 8a)
Affinity DataKi: >1.23E+3nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor and the LSD binding site of the 5-HT2B receptor w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2025
Entry Details
Go to US Patent